- Rösch AG Medizintechnik (SIN 529140), Berlin,
announces that it has granted Henry Schein exclusivity for the sale
of the INJEX(TM) system, the needle-free injection, for the Dental
area in England.
At the beginning of May 2001, Henry Schein as the worldwide
largest producer of health products integrated INJEX(TM) into its
business area Dental in England and Ireland. After sales commencing
very successfully Henry Schein has now been granted exclusivity in
this area of application for England and Ireland.
The short-term sales success has motivated Henry Schein to also
fix by contract distribution in various other countries. Countries
with their own field representatives which would ensure correct
introduction to the INJEX(TM) system, are especially being considered
Topic approval by health insurance companies
Many health insurance companies in Germany, particularly AOK, are
currently in a situation in which they have to increase contribution
payments due to the current financial situation and in which they
immediately have to introduce savings measures. The needle-free
injection system INJEX(TM) offers tremendous potential for savings in
the short-term and on a medium to long-term view.
A prime example for short-term savings opportunities is the
injection of medication at home. Often a nursing service needs to be
financed as patients refuse to inject themselves and the level of
inhibition with regard to injecting cannot be overcome even amongst
family and friends. The use of INJEX(TM) does not require any special
training and the needle-free injection is easily carried out by the
patients themselves. Areas of application in home nursing are
primarily thrombosis prophylaxis, cytokine treatment and insulin
It is particularly the high cost of chronically ill patients such
as diabetics, that heavily strains health insurance companies'
budgets. According to statements by the DDB Bundesverband e.V., per
hour, four diabetics suffer a heart attack, three diabetics have
their lower leg amputated below the knee, two diabetics receive an
artificial kidney and one diabetic loses his/her eyesight, in
Germany. Insurance payments for poorly adjusted diabetes mellitus
amount from DEM 12,000 to DEM 17,000 annually, for well adjusted
diabetes mellitus from DEM 1,500 to DEM 2,500 annually, according to
BKK Elektra and AOK Hessen.
The main reason for this is, on the one hand, the insufficient
education of those involved and, on the other hand, the fear toward
the needle required to inject insulin. With the INJEX(TM) system,
Rösch AG abolishes the inhibition level 'needle'.
ots Originaltext: Rösch AG Medizintechnik
Rösch AG Medizintechnik
Buckower Damm 114
Phone +49 (0) 30 66791537
Fax +49 (0) 30 66791566